PF-07853578

PF-07853578 is an investigational small molecule drug developed by Pfizer for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). It acts as a modulator of patatin-like phospholipase domain-containing protein 3 (PNPLA3), a membrane protein involved in hepatic lipid metabolism. The drug is administered orally and has completed Phase I clinical trials evaluating its safety, tolerability, and pharmacokinetics in healthy adult volunteers. By targeting PNPLA3, particularly relevant in individuals with the PNPLA3 148M risk variant associated with increased liver fat accumulation and mitochondrial dysfunction, PF-07853578 aims to address underlying mechanisms contributing to NASH/MASH pathophysiology.